STOK

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. operates as a biotechnology company. The Company develops antisense oligonucleotide medicines and therapies that increase target gene expression to treat diseases caused by loss of protein function. Stoke Therapeutics serves patients and customers in the United States.

Stoke Therapeutics, Inc. (STOK) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (C). The rating has held at C for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.6 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.5
EV / EBITDA -5.6
Rev Growth YoY 5.9%
Gross Margin N/M
Price Return 3M -17.0%
Price Return 12M 6.2%
Catalyst Signal 0.00
Market Cap $1.7B
TTM Revenue $28.2M
Price / Sales 61.9
ROE -73.6%

Historical Factor Score Progression

Held C for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.6) C (2.4) C+ (2.5) C (2.3) C+ (2.6) C (2.5)
2026-11-08 C+ (2.6) C (2.4) C+ (2.5) C (2.2) C+ (2.6) C (2.5)
2026-11-01 C+ (2.6) C- (1.9) C+ (2.7) C (2.3) C+ (2.7) C (2.4)
2026-10-25 C+ (2.7) C- (2.0) C+ (2.6) C- (2.0) C+ (2.6) C (2.4)
2026-10-18 C+ (2.7) C- (2.0) C+ (2.6) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 4